Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model.
P-873 is a novel compound in the RX-04 pyrrolocytosine series of protein synthesis inhibitors currently under development by Rib-X Pharmaceuticals. We evaluated the pharmacodynamic and pharmacokinetic properties of this compound against Klebsiella pneumoniae using a murine neutropenic thigh infection model. P-873 demonstrated potent and rapid in vivo activity against this organism with enhanced penetration and duration of exposure in thigh tissue.
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Lucinda M
LM
Lamb
Jared L
JL
Crandon
David P
DP
Nicolau
D000818:Animals; D005260:Female; D007710:Klebsiella Infections / Q000188:drug therapy*; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000472:pathogenicity*; D051379:Mice; D009503:Neutropenia / Q000188:drug therapy* / Q000382:microbiology*; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use*; D013848:Thigh / Q000382:microbiology*
D011500:Protein Synthesis Inhibitors